LATEST MANUSCRIPTS IN Exploration of Targeted Anti-tumor Therapy
Gerhard Hamilton, Sandra Stickler, Barbara Rath. Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 1027-1038
Afrooz Mazidimoradi, Samane Sabet Birjandi, Hamid Salehiniya. Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 1039-1058
Marzieh Tahmasebi, Masoud Veissi, Seyed Ahmad Hosseini, Amir Jamshidnezhad. Effect of vitamin D supplementation on inflammatory markers and total antioxidant capacity in breast cancer women using a machine learning technique.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 1059-1070
Abrahams Ocanto, Xabier Mielgo-Rubio, Javier Luna Tirado, Nuria Linares Mesa, Marta López Valcárcel, Sara Pedraza, Victoria Vera Barragan, Patricia Valencia Nieto, Juan Zafra Martín, Felipe Couñago. Coronavirus disease 2019 and lung cancer: where are we?Exploration of targeted anti-tumor therapy. 2023, 4 (5): 1082-1094
Levi Arnold, Juan Pineda Gomez, Michael Barry, Marrion Yap, Laura Jackson, Thuc Ly, David Standing, Subhash B Padhye, Bernhard Biersack, Shrikant Anant, Sufi Mary Thomas. Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 1104-1121
Youjun Li, Michael Karin, Edward V Prochownik. Cholesterol esterification and p53-mediated tumor suppression.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 1122-1127
Zelmira Ballatore, Amalia Goudas, Francesco Bozzi, Alessandra Lucarelli, Michela Burattini, Giulia Ricci, Francesco Savino, Rossana Berardi. A single experience in the conduction of clinical trial during COronaVIrusDisease-2019 pandemic.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 793-800
Gowri Palanissami, Solomon F D Paul. AGEs and RAGE: metabolic and molecular signatures of the glycation-inflammation axis in malignant or metastatic cancers.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 812-849
Parth Malik, Ruma Rani, Raghu Solanki, Vishal Haribhai Patel, Tapan Kumar Mukherjee. Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies.Exploration of targeted anti-tumor therapy. 2023, 4 (5): 850-895